Voriconazole is used to treat invasive fungal disease and the optimal dose regimens 27 are still unknown in cirrhotic Patients. The aim of this study was to determine the 28 safety, to describe pharmacokinetics characteristics, and to optimize dosage regimens 29 of voriconazole in cirrhotic patients. Data pertaining to voriconazole were collected 30 retrospectively and analyzed using a population pharmacokinetics model. A total of 31 219 trough concentrations (C min ) from 120 patients were analyzed. 32 Voriconazole-related adverse events developed in 29 patients, with 69.0% of AEs 33 developing within the first week after voriconazole treatment. The threshold C min for 34 AEs was 5.12 mg/L. A one-compartment model with first-order absorption and 35 elimination adequately described the data. The Child-Pugh class was the only 36 covariate in final model. Voriconazole clearance in patients with Child-pugh A and B 37 cirrhosis (CP-A/CP-B) and Child-pugh C cirrhosis (CP-C) were 1.79 L/h and 0.99 L/h, 38 respectively, the volume of distribution was 159.6 L, and the oral bioavailability was 39 91.8%. The elimination half-life was significantly extended for up to 61.8 -111.7 h in 40 cirrhotic patients. Model-based simulations showed that the appropriate maintenance 41 doses are 75 mg/12 h and 150 mg/24 h intravenously or orally for CP-A/CP-B 42 patients, and 50 mg/12 h and 100 mg/24 h intravenously or orally for CP-C patients. 43
Introduction 50
Liver cirrhosis is a late stage of hepatic fibrosis and is a leading cause of death 51 worldwide (1). Due to the immunocompromised state of cirrhotic patients and their 52 requirement for use of steroids and broad-spectrum antimicrobial agents, as well as 53 invasive procedures, invasive fungal disease (IFD) constitutes an important cause of 54 morbidity in patients with liver cirrhosis (2) (3) (4) . Voriconazole is a triazole antifungal 55 agent with activity against a broad spectrum of clinically significant fungal pathogens, 56 and it is used to treat and prevent IFD in clinical practice (5, 6) . 57
Voriconazole is metabolized primarily by the CYP2C19 isoenzyme while CYP2C9 58 and CYP3A4 contribute to a minor extent, and the large inter-and intra-individual 59 variabilities of voriconazole pharmacokinetics are associated with CYP2C19 genetic 60 polymorphisms, liver dysfunction, drug-drug interaction and food intake (7-9). The 61 voriconazole trough concentration (C min ) is associated with treatment efficacy and 62 safety (10, 11) , and voriconazole C min ranging from 1 -5 mg/L was identified as the 63 therapeutic target with appropriate clinical efficacy and safety (12) . However, the 64 reduced hepatic blood flow and enzyme activity in patients with liver cirrhosis can 65 theoretically lead to voriconazole accumulation and make patients at risk of adverse 66 events (AEs). Therefore, the voriconazole package insert recommends that while the 67 standard loading dose regimens should be used, the maintenance dose should be 68 halved in patients with Child-pugh A and B cirrhosis (CP-A/CP-B) (13). However, 69
there is no recommended voriconazole regimen for patients with Child-pugh C 70 4 cirrhosis (CP-C). Meanwhile, our previous study demonstrated that the halved dose 71 still leads to a supratherapeutic level in the majority of cirrhotic patients, with a 72 voriconazole C min of 4.02 ± 2.00 mg/L (14, 15) . 73
The present study aimed (1) to describe the pharmacokinetics characteristics and 74 safety of voriconazole, and identify the factors influencing pharmacokinetics 75 variability; and (2) to establish the optimal intravenous and oral voriconazole doses 76 with an appropriate efficacy and safety profile in patients with liver cirrhosis. 77 78 2. Results 79
Patient characteristics 80
The demographic and clinical characteristics of the study population are presented in 81 Table 1 . The distributions of the initial voriconazole C min , as sampled before dosage 82 adjustment, in relation to the different dosage regimens are shown in Figure 1 . There 83 were 40 CP-A/CP-B patients and 80 CP-C patients. Voriconazole C min was measured 84 in 219 samples (median of 1 per patient; range 1 -7), and the median sampling time 85 was 6 days (range 3 -37 days) after the first dose. The initial voriconazole C min was 86 measured at a median time of 5 days (range, 3 -27 days) after voriconazole was 87 administered. 88
Voriconazole C min and adverse events 89
Voriconazole-related AEs appeared in 29 (24.2%) patients. The most common AEs 90 were neurotoxicity, visual disturbances and hallucination. The median voriconazole 91 5 C min in patients with AEs was 5.98 mg/L (range, 2.37 -15.10 mg/L), and the median 92 time from voriconazole treatment initiation to the development of AEs was 6 days 93 (range, 2 -15 days) (Table 2) . Additionally, 69.0% (20/29) of voriconazole-related 94
AEs developed within the first week after voriconazole treatment. The voriconazole 95 C min at the time of AEs emerging differed significantly from the initial C min among 96 patients without AEs (median 5.98 mg/L vs 4.76 mg/L, P = 0.045). The CART 97 analysis showed that voriconazole-related AEs were more likely to occur in patients 98 with C min > 5.12 mg/L (P = 0.014). The incidence rates of AEs for patients achieving 99
C min values of >5.12 mg/L and 5.12 mg/L were 32.8% and 16.1%, respectively. 100
Population pharmacokinetics analysis 101
When each covariate was tested separately, the Child-Pugh class, toal bilirubin 102 (TBIL), Child-Pugh score, international normalized ratio (INR), MELD score, 103 gamma-glutamyl transferase (GGT), aspartate transaminase (AST), alkaline 104 phosphatase (ALP), platelet (PLT), age, and alanine transaminase (ALT) showed 105 significant impacts on the CL of voriconazole. The type of cirrhosis, body weight and 106 CYP inducer or inhibitor did not significantly influence voriconazole parameters in 107 this population. The incorporation of the Child-Pugh class as a covariate in the basic 108 model on CL resulted in a significant reduction in OFV (△OFV = 28.1). The Table 3 . 123
The parameters of the final PPK model were close to the mean bootstrap values and 124 all included in the 95% CI. The VPC showed that most of the observed data were fell 125 within the 90% prediction interval ( Figure S1 ). 126
Simulations 127
The lack of effect of weight on voriconazole pharmacokinetics parameters does not 128 support weight-adjusted dosing in patients with liver cirrhosis. Figure 3 and Figure S2  129 show the simulated concentration-time profiles between 0 h and 420 h calculated for 130 the different dosage regimens. The probabilities of simulated voriconazole C min values 131 of <1 mg/L, 1-5 mg/L, and >5 mg/L with different oral and intravenous regimens in 132 liver cirrhotic patients are presented in Table 4 and Table S1 . The results of the 133 7 simulations showed that the halved dose in CP-A/CP-B and CP-C patients could lead 134 to a majority of cases for C min over the supratherapeutic target (5 mg/L). Regarding 135 the C min target for efficacy and safety, the results of the simulations suggested that 136 maintenance dosage regimens of 75 mg/12 h and 150 mg/24 h intravenously or orally 137 for CP-A/CP-B patients, and of 50 mg/12 h and 100 mg/24 h intravenously or orally 138
for CP-C patients are appropriate, since the predicted probability of achieving the 139 therapeutic target concentration in the steady state was 59.0% -68.2% for these 140 optimal regimens in patients with liver cirrhosis. 141 142
Discussion 143
The rationality of halving the voriconazole dose in CP-A/CP-B patients has not been 144 validated widely in clinical practice, and the optimal dose in CP-C patients remains to 145 be established. The present study used a PPK analysis to identify the potential source 146 of pharmacokinetics variability and to optimize the dosage regimens in patients with 147 liver cirrhosis. 148
To our knowledge, this is the first time that voriconazole PPK properties have been 149 characterized in patients with liver cirrhosis. In the present study, single-or 150 multiple-trough samples were collected from patients. These features restricted the 151 ability to estimate k a and V d accurately, which may have an impact on the simulated 152 peak concentration of voriconazole. In the process of constructing the basic model, 153
the OFV value of the model was 532.6 and 535.5, respectively, when k a was fixed to a 154 8 value of 0.5 h -1 (16) or 1.1 h -1 (17), as reported elsewhere. However, we found that the 155 variabilities of k a and F were very small when the NONMEM software was used to 156 calculated k a instead of giving a fixed value, and a OFV value of 508.6 was observed 157 in the process. Thus, the basic model in this study did not include k a and F variability, 158 and a k a value of 0.25 h -1 was calculated, which is similar to previously reported 159 values (0.53 h -1 to 1.1 h -1 ) (16-18). Actually, delayed gastric emptying in cirrhotic 160 patients could delay the absorption of drugs by the small intestine (19). The estimated 161 bioavailability of voriconazole in this study was 91.8%, which was slightly higher 162 than previously reported values for adult patients (63.0% -89.5%) (17, 18, 20, 21) . 163
Theoretically, the reduced liver blood flow and enzyme activity in cirrhotic patients 164 can substantially reduce the first-pass effect, which results in greater systemic 165 availability (22) . 166
Like the Child-Pugh class, the nine potential covariates (TBIL, Child-Pugh score, INR, 167 MELD score, GGT, AST, ALP, PLT, and ALT) are also indicators of liver function, 168 and so these nine covariates and the Child-Pugh class were not incorporated in a 169 model simultaneously. Additionally, the simultaneous addition of Child-Pugh class 170 and age did not lead to a further significant decrease in OFV. Thus, the Child-Pugh 171 class was found to influence voriconazole CL and was the only covariate included in 172 the final model. As the samples were trough values, the CL can be accurately 173 estimated using PPK method. The estimated typical values of CL for CP-A/CP-B and 174 CP-C patients were 1.79 L/h and 0.99 L/h, respectively, which suggest that different 175 9 dosing regimens need to be administered depending on the Child-Pugh class. The 176 calculated CL in cirrhotic patients is much lower than that in patients with normal 177 liver function (17, 21) . Actually, the Child-Pugh class is the most-common method 178 used to classify liver impairment and to adjust the dose of drugs in patients with liver 179 cirrhosis (23, 24), which mainly due to liver disease being clearly associated with 180 reduced liver blood flow and enzyme activity (22). The elimination t 1/2 value of 181 voriconazole is significantly prolonged in patients with liver cirrhosis, and so we 182 believe that it is sufficient to administer voriconazole once daily in cirrhotic patients. 183
The final PPK model appeared to describe the data very well and to be reliably 184 validated, making it adequate for further dosing simulations. The results of the 185 simulations showed that 32.5 -36.7% and 60.7 -66.2% of CP-A/CP-B and CP-C 186 patients, respectively, had a C min exceeding the supratherapeutic target on at day 14 187 after they had received the halved dose (Table 4 and Table S1 ). Thus, the halved dose 188 may be inappropriate in cirrhotic patients for an amount of supratherapeutic 189 voriconazole C min emerged. For CP-C patients, only Yamada et al. (25) . has provided 190 an optimal voriconazole maintenance dose in CP-C patients; those authors used 191 clinical data from six CP-C patients and concluded that the oral voriconazole 192 maintenance doses should be reduced to one-third of the normal dose. However, the 193 results obtained in the present model-based simulations indicate that voriconazole 194 maintenance doses in cirrhotic patients should be reduced to one-fourth for CP-C 195 patients and to one-third for CP-A/CP-B patients compared to that for patients with 196 10 normal liver function. These optimal dosage regimens could ensure that >60% of 197 patients will achieve a C min within the therapeutic target. Notably, TDM was also 198 necessary in patients who received the optimal dosage regimens, since 20 -30% of 199 them exhibited C min values that exceeded the supratherapeutic target. Furthermore, 200
further clinical studies are needed to investigate the safety and efficacy of these 201 optimal dosage regimens in adequate numbers of cirrhotic patients. 202
This study found a clear association between voriconazole C min and AEs, and that the 203 threshold C min for identifying patients with a higher risk of AEs was 5.12 mg/L, which 204 is similar to the supratherapeutic target of voriconazole treatment recommended by 205 the guideline from the British Society for Medical Mycology (12). The rate of AEs 206 was higher in this study than previously reported in liver transplant patients (26). A 207 particularly interestingly finding was that 69.0% (20/29) of cases of 208 voriconazole-related AEs developed within the first week after voriconazole treatment, 209 and that the elimination t 1/2 was prolonged, which suggested that implementing 210 accurate initial dose or plasma concentration monitoring as early as possible could 211 avoid the occurrence of AEs. 212
This study was subject to some limitations. First, it couldn't evaluate the 213 hepatotoxicity according to the criteria of the National Cancer Institute in cirrhotic 214 patients. Additionally, this study had a retrospective design. These two factors would 215 reduce the incidence of voriconazole-related AEs. Second, most of patients did not 216 detect CYP2C19 polymorphisms in this study. Our previous study showed that 217 11 voriconazole had a C min of 3.13 ± 2.68 mg/L in poor metabolizers of CYP2C19 with 218 normal liver function who received the recommended dosage regimens (27). This 219 suggests that the effect of liver cirrhosis on voriconazole pharmacokinetics parameters 220 may exceed the effect of the CYP2C19 polymorphism. Third, the number of 221
Child-Pugh Class A patient was too small (n = 6), and further studies are needed to 222 optimize voriconazole dosage regimens in these patients. 223 224
Conclusion 225
We have firstly explored the PPK parameters of voriconazole in patients with liver 226 cirrhosis, with the findings suggesting that the optimal voriconazole dosages are 75 227 mg/12 h and 150 mg/24 h intravenously or orally for CP-A/CP-B patients, and 50 228 mg/12 h and 100 mg/24 h intravenously or orally for CP-C patients. To reduce the 229 incidence of voriconazole-related AEs，it is critical to ensure voriconazole C min is 230 <5.12 mg/L by monitoring voriconazole C min early. Clinically, TDM is also needed in 231 liver patients who receive the optimal dosage regimens because C min exceeded the 232 supratherapeutic target in some patients. The present study represents a substantial 233 step forward in determining the optimal dosing regimens in cirrhotic patients, and 234 should be complemented by future clinical studies. 235 236 5. Materials and methods 237
Patients 238 12
We reviewed the laboratory information system from May 2014 to May 2018 at two 239 tertiary hospitals. Patients who treated by voriconazole and therapeutic drug 240 monitoring (TDM) had been performed during antifungal therapy were identified and 241 then screened by applying inclusion criteria of (1) presence of liver cirrhosis, 242
including CP-A, CP-B and CP-C patients and (2) age >18 years, and exclusion criteria 243 of (1) the initial TDM after dose adjustment and (2) missing the values of key 244 covariates. This study was approved by all participating institutional review boards. 245
Finally, we retrospectively collected 120 cirrhotic patients into the analysis. Among 246 these patients, four initial dosage regimens were administered: (1) 
Data collection 255
Data were extracted from laboratory information system and medical records, 256 including voriconazole-related information (C min , timing, amount, route), 257 demographics (age, gender and bodyweight), the type of cirrhosis, laboratory data (the 258 liver, kidney and coagulation function) and concomitant medications (CYP2C19 259 13 inhibitors and inducers). The Child-Pugh score, Child-Pugh class and MELD (Model 260 for end-stage liver disease) score were calculated based on previous criteria (28, 29) . 261
The types of AEs were extracted from medical records, and the causal relationship of 262 AEs with voriconazole treatment was defined according to the CTCAE criteria over 263 the treatment period (30). 264
Blood sampling and analytical assays 265
A C min was defined as a level obtained after 3 days of voriconazole therapy with a 266 loading dose or 5 days of voriconazole treatment without a loading dose, and samples 267 were collected at interval windows of 10 -12 h post-dose. The validated 268 high-performance liquid chromatography (HPLC) assays from participating hospital 269 were used to measure voriconazole concentrations (9, 31). We use blank plasma to 270 dilute the plasma whose concentration was beyond the upper limit of quantification 271 and then measured by HPLC. 272
Population pharmacokinetics model and simulations 273

Population pharmacokinetics model construction 274
A population pharmacokinetics (PPK) analysis was conducted using the data to 275 estimate the typical values and the variabilities of pharmacokinetics parameters in the 276 population, and to identify the factors influencing these parameters. 277
Firstly, a basic model, including structural model and statistical model, was developed 278 to describe the PK properties of voriconazole without consideration of covariate 279 effects. A one compartment model with first-order elimination was found to be 280 14 appropriate as the structural model. The pharmacokinetics parameters, clearance (CL), 281 volume of distribution (V d ), absorption rate constant (k a ) and bioavailability (F) were 282 calculated in this model. An exponential model described the inter-individual 283 variability with a mean of zero and a variance of ω 2 , and a combined error model 284 described residual variability with a mean of zero and a variance of σ 2 . The 285 elimination half-life, t 1/2 , was calculated by the form of ln(2)/(CL/V d ). 286
Next, the effect of each covariate on a single pharmacokinetics parameter was tested 287 in a single functional form separately, with a reduction of the objective function value 288 (OFV) greater than 3.84 considered statistically significant. These retained covariates 289
were then used to construct the PPK model in the forward selection process. A 290 backward elimination process was not used in this study since only one covariate was 291 incorporated in the forward selection process. All of these processes were followed 292 the standard procedure of model building (32). The most appropriate PPK model had 293 to meet the following criteria: (1) the minimal OFV; (2) A reduction in OFV of > 6.83 294 in the process of forward selection; (3) the diagnostic plots were improved compared 295 to the basic model. (4) the covariate should be physiologically plausible. 296
Model validation 297
The precision of voriconazole parameters and the robustness of the final model were 298 evaluated using non-parametric bootstrap. A total of 1000 runs were carried out. The 299 visual predictive check (VPC) was used to evaluated the predictive performance of 300 the final voriconazole PPK model. A total of 1000 replicates were simulated, and the 301 15 90% prediction intervals were generated. The simulated results were compared with 302 these observed concentrations in the present study visually. The dashed lines represent the voriconazole target trough plasma concentrations of 1 464 mg/L and 5 mg/L. The solid line is the 50% of simulated data, and the dark grey area 465 and the light gray area are the 50% (Q 25 -75 ) and 90% (Q 5 -95 ) prediction intervals, 466 respectively. 467 Table 1 Demographic and baseline clinical characteristics of patients 468 Rash (n = 3) 6.00 (5.14 -10.65) 4 (4 -7)
Nausea and vomit (n = 2) 4.12, 10.82 13, 15
Hypokalemia (n = 2) 6.71, 8.29 4, 8
Nephrotoxicity (n = 1) 6.17 7
All patients 5.98 (2.37 -15.10) 6 (2 -15) C min : trough concentration. 475 27 477 a CL = θ 1 × e η1 ; V d = θ 2 × e η2 ; k a = θ 3 ; F = θ 4 ; 478 b CL = θ 1 × (1 -θ 5 ×CPG)) × e η1 ; V d = θ 2 × e η2 ; k a = θ 3 ; F = θ 4 ; 479 c CL 1 = θ 1 × e η1 (for CP-C patients); CL 2 = θ 2 × e η2 (for CP-A/CP-B patients); V d = θ 3 × e η3 ; k a = θ 4 ; F = θ 5 .
480
28 Table 4 The probability of simulated voriconazole trough concentrations achieving or 481 not achieving the therapeutic target for different oral dosage regimens in patients with 482 liver cirrhosis. 
